EyeGate Pharmaceuticals Inc (EYEG.OQ)
0.53USD
14 Aug 2018
-- (--)
$0.53
--
--
--
--
225,007
$1.38
$0.29
About
Overall
| Beta: | -- |
| Market Cap(Mil.): | $20.99 |
| Shares Outstanding(Mil.): | 17.20 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| EYEG.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 30.93 | 32.76 |
| EPS (TTM): | -1.30 | -- | -- |
| ROI: | -193.34 | 15.07 | 14.61 |
| ROE: | -241.44 | 16.59 | 16.33 |
BRIEF-EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage Gel
* EYEGATE ADDRESSES MAJORITY OF FDA’S ACTION ITEMS WITH SUBMISSION OF INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR OCULAR BANDAGE GEL
BRIEF-Armistice Capital LLC Reports 50.8 Pct Stake In Eyegate Pharmaceuticals As Of April 13
* ARMISTICE CAPITAL LLC REPORTS 50.8 PERCENT STAKE IN EYEGATE PHARMACEUTICALS INC AS OF APRIL 13 - SEC FILING
BRIEF-Eyegate Announces $11.25 Million Public Offering
* PRICING OF PUBLIC OFFERING OF 35.2 MILLION SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 35.2 MILLION SHARES OF COMMON STOCK
BRIEF-EyeGate Issued New Patent For Iontophoretic Contact Lens Technology
* EYEGATE ISSUED NEW PATENT FOR IONTOPHORETIC CONTACT LENS TECHNOLOGY Source text for Eikon: Further company coverage:
BRIEF-Eyegate Receives FDA Feedback On Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel
* EYEGATE RECEIVES FDA FEEDBACK ON INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL
BRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation Treatment
* EYEGATE COMPLETES ENROLLMENT AND RECEIVES MILESTONE PAYMENT FOR CONFIRMATORY PHASE 3 CLINICAL STUDY OF EGP-437 IN ANTERIOR UVEITIS Source text for Eikon: Further company coverage:
BRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 Mln
* EYEGATE PHARMACEUTICALS FILES FOR POTENTIAL MIXED SHELF OF UP TO $20 MILLION - SEC FILING Source text: (https://bit.ly/2ugghJy) Further company coverage:
BRIEF-Eyegate Pharma Submits Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel
* EYEGATE PHARMA SUBMITS INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL
Estimates